| Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer HJK Ananias, MC van den Heuvel, W Helfrich, IJ de Jong The Prostate 69 (10), 1101-1108, 2009 | 228 | 2009 |
| Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions M Balzar, IH Briaire-de Bruijn, HAM Rees-Bakker, FA Prins, W Helfrich, ... Molecular and Cellular biology 21 (7), 2570-2580, 2001 | 223 | 2001 |
| Therapeutic potential of Galectin‐9 in human disease VR Wiersma, M de Bruyn, W Helfrich, E Bremer Medicinal research reviews 33 (S1), E102-E126, 2013 | 186 | 2013 |
| A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments GA Huls, IAFM Heijnen, ME Cuomo, JC Koningsberger, L Wiegman, ... Nature biotechnology 17 (3), 276-281, 1999 | 174 | 1999 |
| Targeted induction of apoptosis for cancer therapy: current progress and prospects E Bremer, G Van Dam, BJ Kroesen, L de Leij, W Helfrich Trends in molecular medicine 12 (8), 382-393, 2006 | 173 | 2006 |
| Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats Y Wei, P Chen, M de Bruyn, W Zhang, E Bremer, W Helfrich BMC gastroenterology 10, 1-9, 2010 | 140 | 2010 |
| Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor … E Bremer, DF Samplonius, L van Genne, MH Dijkstra, BJ Kroesen, ... Journal of Biological Chemistry 280 (11), 10025-10033, 2005 | 129 | 2005 |
| Target cell‐restricted and‐enhanced apoptosis induction by a scFv: sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 E Bremer, J Kuijlen, D Samplonius, H Walczak, L de Leij, W Helfrich International journal of cancer 109 (2), 281-290, 2004 | 129 | 2004 |
| Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody S Lütje, M Rijpkema, GM Franssen, G Fracasso, W Helfrich, A Eek, ... Journal of Nuclear Medicine 55 (6), 995-1001, 2014 | 128 | 2014 |
| Near-infrared fluorescence (NIRF) imaging in breast-conserving surgery: assessing intraoperative techniques in tissue-simulating breast phantoms RG Pleijhuis, GC Langhout, W Helfrich, G Themelis, A Sarantopoulos, ... European Journal of Surgical Oncology (EJSO) 37 (1), 32-39, 2011 | 122 | 2011 |
| Wnt2 acts as a cell type–specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross‐stimulating the VEGF pathway D Klein, A Demory, F Peyre, J Kroll, HG Augustin, W Helfrich, ... Hepatology 47 (3), 1018-1031, 2008 | 112 | 2008 |
| Target cell–restricted apoptosis induction of acute leukemic t cells by a recombinant tumor necrosis factor–related apoptosis-inducing ligand fusion protein with specificity … E Bremer, DF Samplonius, M Peipp, L van Genne, BJ Kroesen, GH Fey, ... Cancer research 65 (8), 3380-3388, 2005 | 111 | 2005 |
| Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis AJ Stel, B Ten Cate, S Jacobs, JW Kok, DCJ Spierings, M Dondorff, ... The Journal of Immunology 178 (4), 2287-2295, 2007 | 105 | 2007 |
| Antibody-based fusion proteins to target death receptors in cancer M de Bruyn, E Bremer, W Helfrich Cancer letters 332 (2), 175-183, 2013 | 98 | 2013 |
| Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals HJK Ananias, IJ De Jong, RA Dierckx, C de Wiele, W Helfrich, PH Elsinga Current pharmaceutical design 14 (28), 3033-3047, 2008 | 98 | 2008 |
| Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo M de Bruyn, AA Rybczynska, Y Wei, M Schwenkert, GH Fey, ... Molecular cancer 9, 1-14, 2010 | 97 | 2010 |
| CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy FL Komdeur, MCA Wouters, HH Workel, AM Tijans, ALJ Terwindt, ... Oncotarget 7 (46), 75130, 2016 | 91 | 2016 |
| on TRAIL for malignant glioma therapy? JMA Kuijlen, E Bremer, JJA Mooij, WFA Den Dunnen, W Helfrich Neuropathology and applied neurobiology 36 (3), 168-182, 2010 | 90 | 2010 |
| A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability B Ten Cate, E Bremer, M De Bruyn, T Bijma, D Samplonius, ... Leukemia 23 (8), 1389-1397, 2009 | 90 | 2009 |
| Approaches to lung cancer treatment using the CD3E× GP-2-directed Bispecific Monoclonal Antibody BIS-1 BJ Kroesen, J Nieken, DT Sleijfer, G Molema, EGE de Vries, HJM Groen, ... Cancer Immunology, Immunotherapy 45, 203-206, 1997 | 90 | 1997 |
Philip ElsingaFull Professor in PET-Radiochemistry, University Medical Center GroningenVerifisert e-postadresse på umcg.nl
